Sunitinib JGL 50 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sunitinib jgl 50 mg tvrde kapsule

jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - сунитиниб - kapsula, tvrda - urbroj: jedna kapsula sadrži 50 mg sunitiniba

Jakavi Europska Unija - hrvatski - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruxolitinib (kao fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastična sredstva - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Полицитемия vjera (mf)jakavi indiciran za liječenje odraslih bolesnika s полицитемия vjera, koje su otporne na ili netoleranciju hidroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Opzelura Europska Unija - hrvatski - EMA (European Medicines Agency)

opzelura

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostali dermatološki pripravci - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.